Moderna Announces Publication in The New England Journal of Medicine of Interim Results From Phase 1 Study of Its mRNA Vaccine Against COVID-19 (mRNA-1273)
(WorldNews Spain)

Interim analysis of original cohorts of Phase 1 study evaluated two-dose vaccination schedule of mRNA-1273 across three dose levels (25, 100, 250 µg) in 45 healthy adults ages 18-55 years; results reaffirm and expand upon positive interim data announced on May 18th Neutralizing antibody titers were observed in 100% of evaluated participants; at the 100 µg dose level selected for Phase 3, the geometric mean titers were above those seen in convalescent sera Vaccination with mRNA-1273 elicited Th1-biased CD4 T cell responses mRNA-1273 was generally safe and well-tolerated Data support 30,000 participant Phase 3 study expected to begin on July 27 Conference call to be held on Wednesday, July 15...